Celgene Release: Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits In DMARD-Naïve Patients With Active Psoriatic Arthritis

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from a long-term (52-week) phase III trial of OTEZLA, the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in psoriatic arthritis patients who have not had prior treatment with systemic or biologic disease-modifying antirheumatic drugs (DMARDs). The data were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.

Help employers find you! Check out all the jobs and post your resume.